- Generics guidance upgraded again
- MENA revenues up despite geopolitical challenges
Top line growth at Hikma Pharmaceuticals (HIK), best known as a manufacturer of generic drugs, has largely been driven by its fast-growing Injectables division. In the first half, the business saw sales growth of 9 per cent year on year despite a number of headwinds in Middle Eastern and North African (MENA) markets.